{"id":"etripamil-ns","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal discomfort or irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etripamil works by inhibiting L-type calcium channels in the sinoatrial (SA) node and atrioventricular (AV) node of the heart, which slows conduction and reduces heart rate. Its intranasal formulation allows for rapid systemic absorption and quick onset of action, making it suitable for acute conversion of supraventricular tachycardia. The drug's short half-life and rapid offset provide a favorable safety profile with quick reversibility if adverse effects occur.","oneSentence":"Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:49.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute conversion of supraventricular tachycardia to normal sinus rhythm"}]},"trialDetails":[{"nctId":"NCT06716021","phase":"PHASE3","title":"ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3","status":"NOT_YET_RECRUITING","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2027-01","conditions":"Atrial Fibrillation","enrollment":750},{"nctId":"NCT05763953","phase":"PHASE2","title":"The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)","status":"RECRUITING","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2023-12-11","conditions":"Paroxysmal Supraventricular Tachycardia","enrollment":60},{"nctId":"NCT04952610","phase":"PHASE3","title":"Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia","status":"ENROLLING_BY_INVITATION","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2021-12-13","conditions":"Paroxysmal Supraventricular Tachycardia","enrollment":130},{"nctId":"NCT05410860","phase":"PHASE3","title":"Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2022-06-30","conditions":"Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia","enrollment":500},{"nctId":"NCT03635996","phase":"PHASE3","title":"Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302","status":"TERMINATED","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2018-12-10","conditions":"Paroxysmal Supraventricular Tachycardia","enrollment":169},{"nctId":"NCT04467905","phase":"PHASE2","title":"ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2","status":"COMPLETED","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2020-11-19","conditions":"Atrial Fibrillation","enrollment":69},{"nctId":"NCT04072835","phase":"PHASE3","title":"Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303","status":"COMPLETED","sponsor":"Milestone Pharmaceuticals Inc.","startDate":"2019-09-23","conditions":"Paroxysmal Supraventricular Tachycardia","enrollment":1116},{"nctId":"NCT05511870","phase":"PHASE1","title":"A Study of Etripamil in Healthy Subjects","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-03-07","conditions":"Healthy Chinese Subjects","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MSP-2017"],"phase":"phase_3","status":"active","brandName":"Etripamil NS","genericName":"Etripamil NS","companyName":"Milestone Pharmaceuticals Inc.","companyId":"milestone-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue. Used for Acute conversion of supraventricular tachycardia to normal sinus rhythm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}